By the PDA Post Approval Change:
Innovation for Availability of Medicines (PAC iAMSM) Task Force*
The seamless delivery of high quality, effective, and safe medicines
to patients is each drug company’s ultimate duty. However, providing
medication to patients is by no means effortless, as evidenced by the
drug product shortage listings on health authority websites. The
availability of medicines is challenged by a variety of factors, one of
which is global supply chain segmentation due to global regulatory
hurdles imposed on product related post-approval changes (PACs).
Posts
